CN101337026A - External medicine composition for treating gout - Google Patents
External medicine composition for treating gout Download PDFInfo
- Publication number
- CN101337026A CN101337026A CNA200810058822XA CN200810058822A CN101337026A CN 101337026 A CN101337026 A CN 101337026A CN A200810058822X A CNA200810058822X A CN A200810058822XA CN 200810058822 A CN200810058822 A CN 200810058822A CN 101337026 A CN101337026 A CN 101337026A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- gout
- mentholum
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 201000005569 Gout Diseases 0.000 title claims description 37
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 244000056623 Iphigenia indica Species 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- 241000227283 Craibiodendron Species 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 abstract 1
- 241000219061 Rheum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000203383 Schefflera Species 0.000 abstract 1
- 241000489523 Veratrum Species 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 238000002156 mixing Methods 0.000 description 25
- 239000000443 aerosol Substances 0.000 description 23
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 21
- 239000010931 gold Substances 0.000 description 21
- 229910052737 gold Inorganic materials 0.000 description 21
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 206010018634 Gouty Arthritis Diseases 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 230000008961 swelling Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 8
- 229940116269 uric acid Drugs 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000012567 medical material Substances 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 238000004064 recycling Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229940040145 liniment Drugs 0.000 description 5
- 239000000865 liniment Substances 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000005470 impregnation Methods 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000006424 Flood reaction Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000004026 adhesive bonding Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical class FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicament composition for external administration, which cures arthrolithiasis, in particular to a medicament composition for external administration, which cures arthrolithiasis and is prepared from the Chinese medicinal plant herb. The medicament composition for curing arthrolithiasis is a preparation for external administration prepared from the following raw materials by the weight ratio: 16 to 68 parts of Iphigenia indica A.Gray, 16 to 68 parts of scandent schefflera root, 16 to 68 parts of Yunnan craibiodendron leaf, 16 to 68 parts of Tali falsehellebore herb, 16 to 68 parts of amoorcorn tree bark, 16 to 68 parts of bletillae rhizome, 16 to 68 parts of rhubarb and 2 to 10 parts of menthol. The medicament composition for external administration is used for curing the arthrolithiasis disease.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of gout, particularly a kind of is the external medicine preparation compositions of the treatment gout made of raw material with the vegetable Chinese herbal medicine.
Background technology
Gout is because heritability or the acquired cause of disease cause purine metabolism obstacle and serum uric acid to continue the caused disease that raises. it is that excessive production of uric acid or uric acid row are rushed down insufficient uric acid that causes and piled up and cause, uric acid crystal is deposited in cartilage, soft tissue, kidney and joint.Deposition at joint can cause violent pain.Clinical manifestation is that hyperuricemia (hyperuriccmia) and characteristic acute arthritis, tophus form, the tophus chronic arthritis, and urate nephropathy can take place, uric acid lithangiuria etc., and severe patient the joint can occur and disable, renal insufficiency.Gout normal and central obesity hyperlipidemia, diabetes, hypertension and cardiovascular and cerebrovascular disease occur together.
In recent years, along with the raising of China's living standards of the people, life-time dilatation, the change (food that is rich in nucleoprotein increases) of dietary structure, overweight people's increase, the sickness rate of goat also is the trend of rising.Clinical treatment is mainly based on colchicine, nonsteroidal antiinflammatory drug, hormone, promotion urate excretion medicine (as probenecid, sulfinpyrazone and benzbromarone) and inhibition uric acid synthetic drug (allopurinol) at present.Acute period of disease is mainly used colchicine, nonsteroidal antiinflammatory drug, hormone, and the catabasis is mainly used and promotes urate excretion medicine, inhibition uric acid synthetic drug.From clinical, the present kind of anti-gout drugs is few, and is old product mostly, and the untoward reaction of western medicine gout is bigger, has the GI irritation effect as colchicine and indometacin, and the former also produces leucocytes reduction and alopecia etc.; Probenecid, benzbromarone have gastrointestinal reaction, kidney strand carbuncle and excite side effect such as gout acute attack; Allopurinol has serious toxic and side effects such as the allergy of causing, super quick Stevena-Johnson syndrome, bone marrow depression.Effect is not satisfactory, only is applicable to the treatment of acute stage, should not take for a long time.Acute gouty arthritis, i.e. the modal first symptom of gout, its onset is anxious, sharp ache, more than night-time attack, the performance of red and swollen heat pain is arranged around the joint.The first joint of patients more than half is big toe, sole of the foot toe, ankle, knee joint, refer to, wrist, elbow joint also are predilection site, and acute inflammation shows effect repeatedly and can cause joint stiffness, deformity.Bring huge misery to the patient, and few at the external curing medicine of acute gouty arthritis, often be some national folk unguentum, be used for expelling wind and cold, the eliminating impediment pain relieving.Gout mostly belongs to damp and hot numbness category at differential diagnosis in tcm, its pathogenesis or because of the natural endowment deficiency, or because of the eating and drinking without temperance day after tomorrow, visceral dysfunction, distinguish not turbid not normal, so wet, heat, the stasis of blood, the life thereupon of turbid all diseases.This disease is the definite Chinese medicine preparation reliably of inefficacy still at present.
It is to be to allocate Radix Aconiti, Radix Aconiti Kusnezoffii, Flos Carthami, Herba Asari, Rhizoma Et Radix Notopterygii, Herba Achilleae in the wine of 1kg40-65 degree for a Chinese patent 200410036755.3 open " Chinese medicine wine for external use of treatment gout ", makes Chinese medicine wine for external use; Chinese patent 200410040457.1 discloses by Cortex Phellodendri, Rhizoma Coptidis, Herba Taraxaci, Radix Achyranthis Bidentatae, Borneolum Syntheticum and has been prepared into external use plaster; Chinese patent 03117636.4 discloses " a kind of external used medicine for the treatment of gout and preparation method thereof ", and it is to select to comprise that Herba Verbenae, Radix Zanthoxyli Spinifolii, Radix Berberidis, Rhizoma Polygoni Cuspidati, Flos Carthami, Chinese liquor make up, and makes tincture treatment gout.In addition, the Chinese medicine composition of all the other treatment gouts is oral formulations, constitutes more complicated, and the quality of production is restive.Cost is higher, and human body is more or less had certain toxic and side effects.
Summary of the invention
Purpose of the present invention is intended to provide a kind of Chinese medicine for external application for the treatment of gout and preparation method thereof, and this medicine means that some Chinese medicines with therapeutical effect and the substrate combination that suits form.It is to directly act on lesions position, and therapeutic effect is good, and is little to systemic side effects, preparation safe in utilization.
The externally-applied medicinal composition of treatment gout of the present invention is the exterior-applied formulation of being made by following materials of weight proportions: iphigenia indica 16-68 part, stem and leaf of Radix Schefflerae Arboricolae 16-68 part, Folium Craibiodendri Yunnanensis 16-68 part, Herba Veratri Taliensis 16-68 part, Cortex Phellodendri 16-68 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 16-68 part, Radix Et Rhizoma Rhei 16-68 part, Mentholum 2-10 part.
Result of the test shows, in said drug effect medicinal ingredient, especially composition weight effect than for 6 parts of 42 parts of iphigenia indicas, 42 parts of stem and leaf of Radix Schefflerae Arboricolae, 42 parts of Folium Craibiodendri Yunnanensiss, 42 parts of Herba Veratri Taliensis, 42 parts of Cortex Phellodendris, 42 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 42 parts of Radix Et Rhizoma Rhei, Mentholum the time is best
This prescription meets Chinese medical theory, has certain clinical practice basis, cures mainly to be the bonded Chinese medicine compound of disease, and it is prescription under Chinese medical theory instructs: wherein iphigenia indica, Herba Veratri Taliensis, Radix Et Rhizoma Rhei, divinatory symbol by name and, the divinatory symbol preface is placed in the middle, the five elements be wooden, corresponding internal organs: liver, main bone, six colors are gone into green grass or young crops.Iphigenia indica has " heat-clearing and toxic substances removing, dispersing swelling and dissipating binds "; Herba Veratri Taliensis has " vomiting wind-phlegm by emesis, promoting blood circulation to remove blood stasis, reducing swelling and alleviating pain, parasite killing degree "; Radix Et Rhizoma Rhei has: the function of " purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation ".Stem and leaf of Radix Schefflerae Arboricolae, Folium Craibiodendri Yunnanensis belong to feeds, divinatory symbol house by name, and the divinatory symbol preface is placed in the middle, and the five elements are gold, corresponding internal organs: lung, main muscle, six colors are gone into white.Stem and leaf of Radix Schefflerae Arboricolae has " vital energy regualting and blood circulation-promoting, reducing swelling and alleviating pain ", and Folium Craibiodendri Yunnanensis has the function of " eliminating stasis to stop pain, expelling wind and removing dampness ".Cortex Phellodendri belongs to, and divinatory symbol are by name, hangs preface and occupies length, and the five elements are fire, corresponding internal organs: the heart, and main QI and blood, six colors are gone into red, and the function of " heat clearing and damp drying, eliminating fire and detoxication " is arranged.Pseudobulbus Bletillae (Rhizoma Bletillae) in the prescription, Herba Menthae (brain) are the auxiliary medical material of external agent, get the stickup effect that Pseudobulbus Bletillae (Rhizoma Bletillae) has, to strengthen the attaching and the action time of medicine; Utilize the thin cave of Herba Menthae (brain) to convince refrigerant work by patient analysis in order to quick elimination or alleviate the pain and the sense of discomfort of affected part.
This prescription is made external preparation in accordance with the following methods: above-mentioned all the other seven flavor medicine materials except that Mentholum are ground into coarse powder, mixing
(1) flood at twice with 65% ethanol, each 30 days, merge impregnation liquid, filter, collect filtrate;
(2) with 65% ethanol percolation, flooded 48 hours, percolate is collected in diafiltration, leaves standstill 24 hours, filters;
(3) get filtrate in (1) or (2), make aerosol, gel, liniment, medicated wine, tincture, lotion, spray, cataplasma, patch, liniment, ointment according to the following steps respectively:
1. after above-mentioned filtrate being added the Mentholum mixing, medicinal liquid is poured in the clean container, be pressed into third butane or halothane class or gas of dimethyl ether, promptly get aerosol with pressing machine;
2. with above-mentioned filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.20～1.25 (50 ℃); Take by weighing an amount of glycerol, add in the above thick paste, make its abundant mixing dissolve, put cold; With 95% dissolve with ethanol Mentholum, standby with the thick paste mixing that obtains, promptly get gel with gel-type vehicle carbomer or cellulose derivative or sodium alginate or the abundant stirring and evenly mixing of carbopol;
3. above-mentioned filtrate is added Mentholum, mixing, packing promptly gets liniment, medicated wine, tincture, lotion;
4. above-mentioned filtrate is added Mentholum, solvent, antioxidant, surfactant mixing, liquid medicine filling is promptly got spray in sprayer unit;
5. with above-mentioned filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.20～1.25 (50 ℃); Put cold; With 95% dissolve with ethanol Mentholum,, standby with the thick paste mixing that obtains, be prepared into rubber cement with catablasm base material sodium polyacrylate or Sodium Tvlose or mixings such as gelatin, glycerol and micropowder silica gel, after gluing, cutting, lid lining are cut into segment, packing promptly gets cataplasma;
6. with above-mentioned filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.20～1.25 (50 ℃), puts cold, with 95% dissolve with ethanol Mentholum,, standby with the thick paste mixing that obtains, with mixings such as patch substrate ethylene-vinyl acetate copolymer, silicone rubber and Polyethylene Glycol, will mount respectively material, medical mylar and spice are packed in the patch spreading equipment, adjuvant, roll, after the molding, dicing, microwave sterilizating, packing, sealing, packing promptly gets patch;
7. above-mentioned filtrate is added Mentholum, the filmogen polyethylene mixings such as first and second aldehyde or polyvinyl butyral or collodion etc., plasticizer phthalic acid dibutyl ester that contract, packing promptly gets liniment;
8. with above-mentioned filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.20～1.25 (50 ℃), put cold, standby with 95% dissolve with ethanol Mentholum with the thick paste mixing that obtains, promptly get ointment with the ointment base mixing.
Gained gel exquisite quality, color and luster is even, denseness is suitable, stretchability is good, meets regulation under the Chinese Pharmacopoeia gel item.Get product 5g, measure after adding the 25ml distilled water diluting.PH value is 6～8, meets the external preparation acid-base value and is not more than 8.0 requirement.Sample thief is an amount of, is loaded in the hermetic container, places 55 ℃ respectively, and-15 ℃ and room temperature were placed three months, and sample does not have layering, no catabiosis.
Have quick-acting and positioning action after making aerosol, aerosol is sprayed directly on to site of action, is evenly distributed, and is rapid-action; But the medicine airtight package is avoided air, moisture, and the light influence improves medicine stability; Can avoid first pass effect of hepar and gastrointestinal destruction; Local application's zest is little; And aerosol can pass through the proportional valve dosed administration, provides good assurance to the safe handling of poisonous medical material, is better than advantages such as general external preparation.
After making cataplasma skin there are not allergy, irritant reaction, painless and residual when peeling off; Strong to low ionic strength and water-soluble component bearing capacity; In the production process not with an organic solvent, environmentally safe; Higher water content can promote that medicine discharges to skin from patch, and moisture the time can take away heat on the skin in evaporation, brings cooling feeling.
It is remarkable that the present invention treats the curative effect of medication of gout, and do not have overt toxicity and side effect, studies show that through pharmacodynamics test have significant antiinflammatory, analgesic effect, can reducing swelling and alleviating pain, treatment gouty congestion and swelling pain.
In order to prove effectiveness of the present invention and safety, a series of experiments have been carried out.
(1) preliminary acute toxicity test
Carry out the acute toxicity pilot study by " medicine registration management way " requirement.Select percutaneous maximum dosage-feeding test in the rabbit 24 hours, be divided into 2 groups at random, be i.e. blank group and administration group, respectively 3 of every group of male and female with 12 of rabbit.Back part of animal skin is by skin 10cm * 15cm, fasting be can't help water after one night, the administration group gives gold seven beautiful aerosols (present composition) by 15g crude drug/kg.bw skin, and matched group gives 65% ethanol with volume, animal local response and whole body acute toxic reaction after the observation administration.
The result shows, the percutaneous maximum dosage-feeding is 15g crude drug/kg.bw in the gold seven beautiful rabbit 24 hours, and animal skin, the mental status, behavior, diet, outward appearance, secretions, Excreta etc. there is no unusually after the administration.During the experimental observation, do not see that toxicity and death appear in animal, observation in 14 days finishes the back sacrifice of animal is carried out gross anatomy, and the volume of medicine-feeding part skin, each internal organs, organ, color, quality etc. there is no unusually.Seven beautiful groups of rabbit body weight gains of 14 days gold and blank group compare there was no significant difference (p＞0.05) after the administration.
(2) part pharmacodynamic study
1. to the effect of gouty arthritis
1.1 urate is induced the influence of rat gouty arthritis
Get 80 of 180-200g male SD rats, grouping and administration situation see Table 1, for three days on end; After the last administration 30 minutes, except that the blank group the foot pad injecting normal saline 0.05ml of portion of the right side, all the other each groups are induced the generation of gouty arthritis at the injection uric acid sodium normal saline 0.05ml of right side foot pad portion.Respectively with vernier caliper measurement cause scorching before and cause the thickness of the right sufficient pad of scorching back 1h, 2h, 4h, 6h and 8h rat portion so that the difference before and after scorching is as the swelling degree of gouty arthritis, take the mean and matched group relatively, carry out statistical test, the results are shown in Table 1
Table 1 gold seven beautiful aerosols to the influence of rat gouty arthritis (x ± s, n=10)
Compare with blank:
▲ ▲P＜0.05,
▲ ▲P＜0.01.Compare with model group:
*P＜0.05,
*P＜0.01.
Compare with the solvent group:
Result of the test shows: after the urate modeling, model group and blank group relatively have significant difference (P＜0.01), prove the success of the inductive rat gouty arthritis of urate model.With model group relatively gold seven beautiful aerosols high, medium and low dosage group in different time points the inductive rat paw edema of urate is all had significant inhibitory effect, gold seven beautiful aerosol low dose group 1h after modeling have significant inhibitory effect (P＜0.05), show that gold seven beautiful low dosages have the inhibitory action of morning to inflammation.And solvent does not have obvious influence to this model, and prompting gold seven beautiful aerosols are to be caused by medicine to the inhibitory action of inflammation, rather than the solvent generation.
1.2 influence to urate inducing mouse gouty arthritis
Get 80 of 20-23g male mices, grouping and administration situation see Table 2, for three days on end; After the last administration 30 minutes, except that the blank group the foot pad injecting normal saline 0.05ml of portion of the right side, all the other each groups are induced the generation of gouty arthritis at the injection uric acid sodium normal saline 0.05ml of right side foot pad portion.Respectively with vernier caliper measurement cause scorching before and cause the diameter at 0.5cm place under scorching back 1h, 2h, 4h and the 6h mice limb joint so that the difference before and after scorching is as the swelling degree of gouty arthritis, takes the mean and matched group compares, and carries out statistical test.The results are shown in Table 2.
Table 2 gold seven beautiful aerosols to the influence of mice gouty arthritis (x ± s, n=10)
Compare with blank:
▲ ▲P＜0.05,
▲ ▲P＜0.01.Compare with model group:
*P＜0.05,
*P＜0.01.
Compare with the solvent group:
Result of the test shows: after the urate modeling, model group and blank group relatively have significant difference (P＜0.01), prove the success of the inductive mice gouty arthritis of urate model.With model group relatively gold seven beautiful aerosols high, medium and low dosage group in different time points the inductive mice foot swelling of urate is all had remarkable inhibitory action, in the gold seven beautiful aerosols, low dose group 1h after modeling has the inhibitory action (P＜0.01) of highly significant, shows in the gold seven beautiful aerosols, low dosage has early inhibitory action to inflammation; And solvent does not have obvious influence to this model, and prompting gold seven beautiful aerosols are to be caused by medicine to the inhibitory action of inflammation, rather than the solvent generation.
2. to the influence of general inflammation
2.1 xylol causes the influence of mice auricle swelling
Get 70 of 18-22g mices, male and female half and half, grouping and administration see Table 3, and each treated animal every day is auris dextra coating 1 time according to dosage, for three days on end, administration in the 3rd day is after 30 minutes, and 0.05ml caused by dimethylbenzene xylene inflammation is evenly smeared on every Mus auris dextra two sides, causes scorching back 1 hour punctual execution animal, card punch with diameter 8mm downcuts ears with the position homalographic, weigh, as the swelling degree, calculate inhibitory rate of intumesce with the difference of two auricle weight.
Table 3 gold seven beautiful aerosol xylol cause mice auricle swelling influence (x ± s, n=10)
Compare with the blank group:
*＜0.05,
*＜0.01, compare with the solvent group:
Experimental result shows: compare with the blank group, gold seven beautiful aerosol height, middle dosage group can significantly suppress the mice auricle swelling due to the dimethylbenzene, and solvent does not have obvious influence to mice auricle swelling; Prompting gold seven beautiful aerosols are that medicine causes to the inhibitory action of inflammation, rather than the solvent generation.
3. analgesic activity
3.1 influence to the reaction of rat water-bath whipping
Get 70 of 180～200g male rats, grouping and administration see Table 4, for three days on end, before the tail administration and after the administration 30,60,120 and 180 minutes, measure whipping response latency of rat respectively in 55 ± 0.5 ℃ of waters bath with thermostatic control, as the pain threshold index.Take the mean and the comparison of blank group, carry out statistical test, the results are shown in Table 4.
The influence that table 4 gold seven beautiful aerosols react rat water-bath whipping (x ± s, n=10)
Compare with matched group:
*P＜0.05,
*P＜0.01, compare with the solvent group:
Experimental result shows: with the blank group relatively, gold seven beautiful aerosol three dosage groups the be significantly increased pain threshold of rat water-bath whipping and rapid-action, long action time.Solvent does not have obviously influence to this reaction; The analgesic activity of prompting gold seven beautiful aerosols is that medicine causes, rather than the solvent generation.
Test conclusion: gold seven beautiful aerosols have remarkable inhibitory action to inductive rat of urate and mice gouty arthritis, can significantly suppress the mice auricle swelling due to the dimethylbenzene, the response time of significant prolongation rat water-bath whipping.
The specific embodiment
Embodiment 1:
Take by weighing 42 parts of iphigenia indicas, 42 parts of stem and leaf of Radix Schefflerae Arboricolae, 42 parts of Folium Craibiodendri Yunnanensiss, 42 parts of Herba Veratri Taliensis, 42 parts of Cortex Phellodendris, 42 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 42 parts of Radix Et Rhizoma Rhei, 6 part of eight flavor of Mentholum medical material in proportion, seven flavors except that Mentholum are ground into coarse powder, mixing, ethanol with 65% floods at twice, each 30 days, merge impregnation liquid, cold preservation 48 hours, filter, collect filtrate, behind the adding Mentholum mixing, medicinal liquid is poured in the clean container, be pressed into third butane gas with pressing machine, promptly get the aerosol for the treatment of gout.
Embodiment 2:
Take by weighing 35 parts of iphigenia indicas, 35 parts of stem and leaf of Radix Schefflerae Arboricolae, 35 parts of Folium Craibiodendri Yunnanensiss, 35 parts of Herba Veratri Taliensis, 35 parts of Cortex Phellodendris, 35 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 35 parts of Radix Et Rhizoma Rhei, 5 part of eight flavor of Mentholum medical material in proportion, seven flavors except that Mentholum are ground into coarse powder, mixing, ethanol with 65% floods at twice, each 30 days, merge impregnation liquid, filter, collect filtrate; Filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.20～1.25 (50 ℃); Take by weighing an amount of glycerol, add in the above thick paste, make its abundant mixing dissolve, put cold; With 95% dissolve with ethanol Mentholum,, standby with the thick paste mixing that obtains; With the hydrophilic high molecular material is substrate, adds suitable macromolecular material (carbomer, cellulose derivative, sodium alginate etc.) according to routine techniques; Solvent (glycerol, purified water); Nertralizer (triethanolamine, sodium hydroxide); Wetting agent (glycerol, propylene glycol); Percutaneous absorption enhancer (propylene glycol, azone, dimethyl sulfoxide) stirring and evenly mixing.Medical material mixture and the abundant stirring and evenly mixing of substrate are promptly got the gel for the treatment of gout.
Embodiment 3:
Take by weighing 16 parts of iphigenia indicas, 16 parts of stem and leaf of Radix Schefflerae Arboricolae, 16 parts of Folium Craibiodendri Yunnanensiss, 16 parts of Herba Veratri Taliensis, 16 parts of Cortex Phellodendris, 16 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 16 parts of Radix Et Rhizoma Rhei, 2 part of eight flavor of Mentholum medical material in proportion, all the other seven flavor medicine materials except that Mentholum are ground into coarse powder, mixing, ethanol percolation with 65%, flooded 48 hours, percolate is collected in diafiltration, cold preservation 48 hours is filtered; Add Mentholum, mixing, packing promptly gets the liniment for the treatment of gout.
Embodiment 4:
Take by weighing 68 parts of iphigenia indicas, 68 parts of stem and leaf of Radix Schefflerae Arboricolae, 68 parts of Folium Craibiodendri Yunnanensiss, 68 parts of Herba Veratri Taliensis, 68 parts of Cortex Phellodendris, 68 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 68 parts of Radix Et Rhizoma Rhei, 10 part of eight flavor of Mentholum medical material in proportion, seven flavors except that Mentholum are ground into coarse powder, mixing, ethanol with 65% floods at twice, each 30 days, merges impregnation liquid, filter, collect filtrate, with above-mentioned filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.20～1.25 (50 ℃); Put cold; With 95% dissolve with ethanol Mentholum, with the thick paste mixing that obtains, standby, add suitable adhesive, wetting agent, cross-linking agent, filler as substrate according to routine techniques, prepare burden with the extractum of corresponding proportion recipe quantity, be prepared into rubber cement, after gluing, cutting, lid lining, be cut into segment, packing promptly gets the cataplasma for the treatment of gout.
Claims (2)
1, a kind of externally-applied medicinal composition for the treatment of gout is characterized in that the exterior-applied formulation of being made by following materials of weight proportions: iphigenia indica 16-68 part, stem and leaf of Radix Schefflerae Arboricolae 16-68 part, Folium Craibiodendri Yunnanensis 16-68 part, Herba Veratri Taliensis 16-68 part, Cortex Phellodendri 16-68 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 16-68 part, Radix Et Rhizoma Rhei 16-68 part, Mentholum 2-10 part.
2, the externally-applied medicinal composition of treatment gout according to claim 1 is characterized in that the exterior-applied formulation of being made by following materials of weight proportions medicine: 42 parts of iphigenia indicas, 42 parts of stem and leaf of Radix Schefflerae Arboricolae, 42 parts of Folium Craibiodendri Yunnanensiss, 42 parts of Herba Veratri Taliensis, 42 parts of Cortex Phellodendris, 42 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 42 parts of Radix Et Rhizoma Rhei, 6 parts of Mentholums.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810058822XA CN101337026A (en) | 2008-08-15 | 2008-08-15 | External medicine composition for treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810058822XA CN101337026A (en) | 2008-08-15 | 2008-08-15 | External medicine composition for treating gout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101337026A true CN101337026A (en) | 2009-01-07 |
Family
ID=40211291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810058822XA Pending CN101337026A (en) | 2008-08-15 | 2008-08-15 | External medicine composition for treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101337026A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103341135A (en) * | 2013-05-31 | 2013-10-09 | 广州花海药业股份有限公司 | Gel agent for treating arthralgia and preparing method thereof |
| CN108619344A (en) * | 2018-08-13 | 2018-10-09 | 刘元 | Treat the externally applied drug and preparation method thereof of gout |
| JP2021506967A (en) * | 2017-12-15 | 2021-02-22 | マーク、フーパーＭａｒｋ Ｈｏｏｐｅｒ | Dissolution of monosodium urate to treat gout |
-
2008
- 2008-08-15 CN CNA200810058822XA patent/CN101337026A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103341135A (en) * | 2013-05-31 | 2013-10-09 | 广州花海药业股份有限公司 | Gel agent for treating arthralgia and preparing method thereof |
| CN103341135B (en) * | 2013-05-31 | 2015-04-22 | 广州花海药业股份有限公司 | Gel agent for treating arthralgia and preparing method thereof |
| JP2021506967A (en) * | 2017-12-15 | 2021-02-22 | マーク、フーパーＭａｒｋ Ｈｏｏｐｅｒ | Dissolution of monosodium urate to treat gout |
| CN111491625B (en) * | 2017-12-15 | 2023-12-01 | 贺亮 | Dissolving monosodium urate for treating gout |
| CN108619344A (en) * | 2018-08-13 | 2018-10-09 | 刘元 | Treat the externally applied drug and preparation method thereof of gout |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100542585C (en) | A kind of externally-applied medicinal composition with analgesia and antiinflammatory action | |
| KR101445010B1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition, preparative method and usage thereof | |
| CN101181559B (en) | Preparation method of traditional Chinese medicine preparation for treating fungal skin diseases | |
| CN103041173A (en) | Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof | |
| CN101664482B (en) | Externally-applied medicine for treating beriberi and skin pruritus and preparation method thereof | |
| CN103751734B (en) | Blood circulation invigorating and pain relieving adhesive plaster and preparation method thereof | |
| CN102743662B (en) | Zhuang medicine preparation for treating gynecological inflammation and preparation method thereof | |
| CN102579658A (en) | Traditional Chinese medicinal composition for curing hyperuricacidemia, gout and urinary retention | |
| CN101337026A (en) | External medicine composition for treating gout | |
| CN102940822B (en) | Synovitis treating medicine and preparation method thereof | |
| CN101744973A (en) | Chinese medicinal extractum and extraction process thereof | |
| CN101069698A (en) | Method for preparing termite fugus gardens extract and use thereof | |
| CN111358906A (en) | Traditional Chinese medicine composition suitable for exogenous diseases | |
| CN104225386B (en) | A kind of compound thunder god vine gel cream of high-efficiency low-toxicity and preparation method thereof | |
| CN106377604A (en) | Antibacterial inflammation diminishing and itching relieving traditional Chinese medicine ointment and preparation method thereof | |
| CN1311854C (en) | Medicinal composition for treating traumatic surface | |
| WO2019142042A1 (en) | Synergistic medicinal preparation for treating skin disorders like tinea versicolor | |
| CN104435126A (en) | Traditional Chinese medicine preparation for improving rheumatic arthralgia and resisting fatigue and preparation method thereof | |
| CN106267134A (en) | A kind of anti-inflammatory analgesic Chinese medicine composition and preparation method thereof | |
| CN116036225B (en) | A naturally derived external pharmaceutical composition for treating arthritis | |
| CN102526384A (en) | Medicament for treating rheumatism and preparation method thereof | |
| CN108143769A (en) | A kind of deep medicine puree and preparation method of Chinese medicine external treatment rheumatic arthritis | |
| CN101721437A (en) | Medicine composition used for treating chronic pharyngitis and preparation method thereof | |
| CN107929624A (en) | A kind of ointment for treating tinea pedis and preparation method thereof | |
| CN106177352A (en) | The cold compress bag for the treatment of rheumatoid arthritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090107 |